Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Year: 2022
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Caicun Zhou, Ziping Wang, Yuping Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Jianhua Chang, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Jingru Wang, Peiqi Li, Mengmeng Qin, Dongmei Lu, Jason Yang
Institutions: Tongji University, Shanghai Pulmonary Hospital, Peking University Cancer Hospital, Shandong Tumor Hospital, Jinan Central Hospital, University of Science and Technology of China, Anhui Provincial Hospital, Zhengzhou University, Henan Cancer Hospital, China Medical University, Third Affiliated Hospital of Harbin Medical University, Sichuan Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University, Fudan University Shanghai Cancer Center, Hunan Cancer Hospital, Fujian Provincial Cancer Hospital, First Hospital of Jilin University, Zhejiang University, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Second Affiliated Hospital of Zhejiang University, CStone Pharmaceuticals (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4205569586